🇺🇸 FDA
Patent

US 12421269

SGLT2/DPP4 inhibitor and application thereof

granted A61PA61P3/10

Quick answer

US patent 12421269 (SGLT2/DPP4 inhibitor and application thereof) held by CGeneTech (Suzhou, China) CO., Ltd. expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CGeneTech (Suzhou, China) CO., Ltd.
Grant date
Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61P, A61P3/10